BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Painful Lumbar RadiculopathySciaticaRadiculopathy
Interventions
DRUG

BG00010

As specified in the treatment arm

DRUG

Placebo

As specified in the treatment arm

Trial Locations (25)

16635

Research Site, Duncansville

27103

Research Site, Winston-Salem

27612

Research Site, Raleigh

31406

Research Site, Savannah

31904

Research Site, Columbus

32789

Research Site, Winter Park

32806

Research Site, Orlando

33312

Research Site, Fort Lauderdale

33351

Research Site, Sunrise

33606

Research Site, Tampa

33713

Research Site, St. Petersburg

34232

Research Site, Sarasota

47714

Research Site, Evansville

60657

Research Site, Chicago

61701

Research Site, Bloomington

66210

Research Site, Overland Park

68521

Research Site, Lincoln

78731

Research Site, San Antonio

84106

Research Site, Salt Lake City

85018

Research Site, Phoenix

90717

Research Site, Lomita

90806

Research Site, Long Beach

91105

Research Site, Pasadena

93710

Research Site, Fresno

02301

Research Site, Brockton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT01873404 - BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy | Biotech Hunter | Biotech Hunter